Boston 3T Biotechnologies Inc.

Boston 3T Biotechnology's technology in development is designed to cure cancer, through the use of therapeutic T Cell technology.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Woburn, MA, USA
  • Currency USD
  • Founded October 2012
  • Employees 3

Company Summary

Through our patent pending cancer technologies, we address both the humanitarian as well as the economic issues relating to cancer, both solid, as well as liquid tumors. We have passed the "discovery stage", and are ready to enter the next stage of testing . Our targeted customer will likely be a large pharmaceutical company to partner with Boston 3T Biotechnology through a licensing or sales of our technology.

Team

  • Meijia Yang
    PhD

    Education and Experiences:
    Post Graduate Fellow, Stony Brook University, Stony Brook, NY
    Post Graduate Fellow, Dartmouth Medical School, Hanover, NH
    PhD in Biochemistry, University of Basel, Switzerland
    University of Freiburg, Germany , Diploma in Biology
    Member of Sino-American Pharmaceutical Professionals Association (SAPA-New England)

  • Min Yang
    PhD

    Education and Membership
    Postdoctoral Fellow. Molecular Immunology, Yale School of Medicine, New Haven, CT
    Ph.D. Molecular Biology, State University of New York at Buffalo, Buffalo, NY
    B.S., Biochemistry, Fudan University, Shanghai, China
    American Association for Cancer Research (AACR)
    International Society for Biological Therapy of Cancer (iSBTC)
    The American Association of Immunologists (AAI)
    Overseas Chinese-American Entrepreneurs As

  • John Goldman

Advisors

  • Foley & Hoag
    Lawyer
    Unconfirmed
    Not selected as of this date
    Accountant
    Unconfirmed

Previous Investors

  • Friends and family to date
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free